DFDA

Azithromycin

Treatment for Pertussis

Typical Dosage: Infants <6 months: 10 mg/kg/day; Older: 500 mg Day 1, then 250 mg daily

Effectiveness
88%
Safety Score
70%
Clinical Trials
4
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
70
DangerousModerateSafe
Treatment Details
Dosage Range
Infants <6 months: 10 mg/kg/day; Older: 500 mg Day 1, then 250 mg daily
Time to Effect
1-2 days (bacterial eradication)
Treatment Duration
5 days
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$600
Side Effect Mgmt:$5
Total Annual:$625
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$31.25
Cost per Remission
$33.33
Prescription Access Economics
Annual Societal Loss per Patient
$-2,795
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$150/year
Time Cost
$30/year
Travel + wait time
Insurance Admin Cost
$15/year
Prior auth, claims
Rx Price
$20/year
Potential OTC Price
$10/year
Estimated if OTC available
Early Treatment Benefit
+0.02 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
LOW
Azithromycin Outcomes

for Pertussis

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+80%
Remission Rate
+75%
Common Side Effects
Diarrhea
+8%
Nausea
+6%
Abdominal pain
+4%
QT prolongation
+0.1%

Sources:

researchgate.net
bmj.com
mdedge.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Azithromycin in Pertussis

Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks

NCT05847322RECRUITINGNA
View Study
72 participants
INTERVENTIONAL
Southampton, United Kingdom
Started: Dec 6, 2022
Completed Clinical Trials
2 completed trials for Azithromycin in Pertussis

Pertussis Challenge Study in Adults Vaccinated With BPZE1

NCT05461131COMPLETEDPHASE2
View Study
53 participants
INTERVENTIONAL
Oxford, United Kingdom +1 more
Started: Jun 20, 2022

Vanderbilt Pertussis Exposure Study: PEP in Vaccinated Healthcare Workers Following Pertussis Exposure

NCT00469274COMPLETEDNA
View Study
1.1K participants
INTERVENTIONAL
Nashville, United States
Started: May 1, 2007